JOURNAL ARTICLE

Lilly Invests $5.3 Billion to Boost Weight-Loss Drug Supply.

  • Published In: Bloomberg.com, 2024. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Muller, Madison; Almeida, Isis 3 of 3

Abstract

Eli Lilly & Co. plans to invest $5.3 billion to increase production of the key ingredient in its weight-loss and diabetes drugs due to high demand and shortages. The investment will expand a facility in Indiana that produces tirzepatide, the active ingredient in Zepbound and Mounjaro. This move is part of a larger trend of companies bringing manufacturing processes back to the US, making supply chains more resilient and less vulnerable to geopolitical tensions. The investment is expected to create jobs and have a positive impact on communities. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2024/05, pN.PAG
  • Document Type:Proceedings
  • Subject Area:Health and Medicine
  • Publication Date:2024
  • Accession Number:177460630
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.